Question 1

Am I eligible for this trial based on my current health and treatment history?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer clinical trial (NCT03685331). Contact the study team or your healthcare provider for specific answers.

Question 2

How does this combination treatment compare to my current options?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer clinical trial (NCT03685331). Contact the study team or your healthcare provider for specific answers.

Question 3

What potential side effects should I expect from these medications?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer clinical trial (NCT03685331). Contact the study team or your healthcare provider for specific answers.

Question 4

How often would I need to come in for visits and treatments?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer clinical trial (NCT03685331). Contact the study team or your healthcare provider for specific answers.

Question 5

What happens if I experience side effects or my condition worsens during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer clinical trial (NCT03685331). Contact the study team or your healthcare provider for specific answers.

Question 6

Are there any additional tests or procedures I would need to undergo if I participate?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer clinical trial (NCT03685331). Contact the study team or your healthcare provider for specific answers.

What this study is about